Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05751759 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment
A Phase 1 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT05751759 is a Phase 1 study that has completed, run by AstraZeneca. The registered enrollment target is 31 participants.
The verdict
NCT05751759, a Phase 1 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of mitiperstat.
Interventions
- DRUG Mitiperstat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2023-03-20 |
| Est. Completion | 2024-11-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05751759
The ClinicalTrials.gov registry entry for NCT05751759 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Mitiperstat is the first listed.
NCT05751759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05751759 about?
NCT05751759 is a clinical study titled "Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment". This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of mitiperstat.
What is the current status of trial NCT05751759?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2023-03-20. Estimated completion is 2024-11-21.
What interventions are being tested in trial NCT05751759?
The interventions under investigation include: Mitiperstat (DRUG).
Who is sponsoring clinical trial NCT05751759?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.